Our Mission

Established in 2013, the Oklahoma Clinical and Translational Science Institute serves as a catalyst for clinical and translational research that improves health and healthcare for underserved and underrepresented populations, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Shared Clinical and Translational Resources

OSCTR is Oklahoma's NIH-funded IDeA-CTR that provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in the state

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

​

 

 

 

 

 

OCTSI on the Radio

Submitted by Anonymous (not verified) on

OCAST Oklahoma Innovations will air this Saturday and Sunday on the stations below. It will be available on the OCAST website www.ok.gov/ocast/News_Media/Radio_Show , along with a transcript, on Monday. 

The week's program features OUHSC research leaders discussing science and medicine in Oklahoma. Dr. Judith James, the Principal Investigator of the Oklahoma Shared Clinical and Translational Resources discusses the Oklahoma Clinical and Translational Science Institute and our projects. 

Subscribe to News

Recent Publications

Pilot implementation and qualitative evaluation of a financial hardship screening among Native American patients with cancer

Support Care Cancer. 2024 Nov 15;32(12):792. doi: 10.1007/s00520-024-08995-1.

ABSTRACT

PURPOSE: Native American (NA) patients with cancer are at increased risk of financial hardship due to lack of private health insurance coverage, medical comorbidities, and higher poverty rates. We aimed to implement and evaluate a pilot financial hardship screening (FHS) program among NA patients with cancer.

Evaluating COVID-19 vaccine effectiveness during pre-Delta, Delta and Omicron dominant periods among pregnant people in the U.S.: Retrospective cohort analysis from a nationally sampled cohort in National COVID Collaborative Cohort (N3C)

BMJ Public Health. 2024 Jul;2(1):e000770. doi: 10.1136/bmjph-2023-000770. Epub 2024 Jun 3.

ABSTRACT

OBJECTIVES: To evaluate the effectiveness of COVID-19 vaccinations (initial and booster) during pre-Delta, Delta, and Omicron dominant periods among pregnant people via (1) COVID-19 incident and severe infections among pregnant people who were vaccinated vs. unvaccinated and (2) post-COVID-19 vaccination breakthrough infections and severe infections among vaccinated females who were pregnant vs. non-pregnant.

Upcoming Events

Media

Copyright © 2025 The Board of Regents of the University of Oklahoma. All rights reserved
Disclaimer | Copyright | Equal Opportunity Employer

Built and Managed by the OCTSI. Base theme by Zymphonies